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Introduction {#sec1}
============

Malignant mesothelioma (MM) is a highly aggressive neoplasm most often linked to exposure to asbestos fibers, which induce chronic inflammation and perpetual tissue repair by the surrounding mesothelial cells. Chronic hyper-proliferation leads to a series of genetic and epigenetic modifications of these cells gradually developing into malignant cancer cells and tumor formation ([@bib25]). Therapy generally comprises a combination chemotherapy consisting of cisplatin (cis-Pt) and pemetrexed, at times accompanied by radiotherapy and/or tumor removal by surgery ([@bib10]). The low success rate of treatments is likely caused by a subpopulation of tumor cells characterized by high resistance to chemotherapy and a high tumor-forming potential leading to rapid recurrence, the so-called cancer stem cells (CSCs). Currently no universal markers exist for unambiguously identifying CSCs in MM or other cancer types, possibly linked to the dynamic and heterogeneous properties of CSCs ([@bib1]). Various assays have been described to enrich CSC-containing tumor cell subpopulations: fluorescence-activated cell sorting (FACS) of putative CSCs, sometimes also called tumor-initiating cells (TICs), relies mostly on expression of cell surface markers (CD133, CD44, CD24; [@bib19]; or EpCAM; [@bib30]) or on dye-exclusion assays based on the elevated expression of ABC transporter family members, e.g., ABCG2 ([@bib14]). Alternatively, increased aldehyde dehydrogenase (*ALDH1*) activity characterizes a subpopulation of cancer cells with CSC properties ([@bib11]), also in human MM cell lines ([@bib24]). The currently most comprehensive characterization of CSC subpopulations has allowed the identification of a hierarchical organization, where CSC subpopulations dynamically change between various differentiation states (clusters) ([@bib1]). Each cluster is characterized by a series of genes; CSCs expressing typical (normal) pluripotency stem cell marker genes such as *SOX2*, *NANOG*, and *OCT4* (also named *POU5F1*) were found at the apex of the hierarchy, followed by populations of one to several types of progenitor cell populations expressing genes such as *ALDH1* and *ABCG2*. Thus, CSC-enrichment methods based on stem cell marker expression including SOX2 and OCT4 have been particularly successful in selecting tumor cells with (1) the high tumor-forming potential in vivo, (2) the particular growth properties including self-renewal and asymmetric cell division, (3) the increased chemoresistance, and (4) the aggressiveness shown in other cancer types ([@bib13], [@bib26]). The concept that CSCs within a tumor mass might represent important targets for therapy is now accepted for nearly all cancer types ([@bib28]).

Here, we identified and characterized MM cell subpopulations in vitro based on their increased endogenous expression of SOX2 and OCT4 driving a reporter (EGFP) ([@bib15], [@bib26]). We demonstrate these cells to have different properties with respect to chemoresistance, and that the proportion of these cells appears to be determined intrinsically, also involving asymmetric cell division. Moreover, overexpression of the tumor suppressor NF2 caused an almost complete block of cell proliferation in non-enriched CSC cells, while high SOX2/OCT4-expressing cells selected by the reporter approach were barely affected by forced NF2 expression. Injection of the EGFP(+) cells resulted in an increased frequency, number, and size of tumors in vivo compared with cells with low SOX2/OCT4 expression. These results are indicative of a CSC-enriched population in MM cell lines of human and mouse origin likely relevant for tumor relapse.

Results {#sec2}
=======

Identification and Initial Characterization of High SOX2/OCT4-Expressing Human CSC-Enriched MM Cells {#sec2.1}
----------------------------------------------------------------------------------------------------

To identify putative CSCs in MM, we relied on a tool initially developed for stem cell biology ([@bib15]). In this lentivirus-based approach, MM cells of human and mouse origin were infected with a construct that contains SOX2- and OCT4-binding sites in the promoter region, followed by an expression cassette coding for EGFP and an IRES connecting to a puromycin-resistance cassette ([Figure 1](#fig1){ref-type="fig"}A). Thus, cells expressing high levels of SOX2/OCT4 can be identified by EGFP expression and, moreover, selected/isolated by their puromycin resistance and/or by FACS. The overall lentiviral transduction efficiency in MM cell lines was assessed with a constitutive NLS-mCherry construct ([Figures S1](#mmc1){ref-type="supplementary-material"}B and S1C). FACS analyses revealed approximately 85% of cells to show red fluorescence; an overlay of bright field and fluorescence images from transduced ZL55 and RN5 MM cells and visual inspection indicated that the transduction efficiency was likely even higher, i.e., in the order of \>90% ([Figure S1](#mmc1){ref-type="supplementary-material"}B). In the population of infected ZL55 cells named ZL55-SO cells, we observed approximately 5% of EGFP-expressing (EGFP(+)) cells ([Figure 1](#fig1){ref-type="fig"}B). A similar percentage of high SOX2- and OCT4-expressing EGFP(+) cells (ZL55 ≈ 4%; [Figure S1](#mmc1){ref-type="supplementary-material"}A3) was obtained with the SORE6 reporter construct previously used in breast cancer cells ([@bib26]). This percentage lies within a similar range to that observed for the ZL55 side population (2% SP cells, [@bib12]) or ALDEFLUOR-positive(+) MM87 cells (3.8%; [@bib24]). Quantitative analyses by FACS showed 4.86% of ZL55-SO cells to express sufficiently high levels of SOX2 and OCT4 to drive EGFP expression ([Figure 1](#fig1){ref-type="fig"}C). ZL55-SO cells subjected to puromycin (2 μg/mL) selection for 7 days revealed the surviving cell population to show variable EGFP expression and were named ZL55-SO-P2. In order to exclude likely EGFP-negative or low EGFP-expressing cells in the quantitative FACS analyses, based on the stringent FACS settings, 78.6% of ZL55-SO-P2 cells fulfilled the criteria to be unmistakably identified as EGFP(+) cells ([Figure 1](#fig1){ref-type="fig"}D); yet, by eye, essentially all cells appeared to emit green fluorescence ([Figure 1](#fig1){ref-type="fig"}E). In addition, we generated ZL55-SO-P10 cells, where the puromycin concentration was augmented to 10 μg/mL aimed at selecting cells with the highest levels of SOX2 and OCT4. Expression levels (mRNA) of *SOX2*, *OCT4*, as well as previously proposed MM CSC markers including *ABCG2* and *CSF1R*, all implicated in mesothelioma chemoresistance, were considerably increased (on average 3- to 5-fold) in puromycin-selected ZL55-SO cells ([Figure 1](#fig1){ref-type="fig"}F). The largest increase from -P2 to -P10 cells was observed for *OCT4* ([Figure 1](#fig1){ref-type="fig"}F). Experiments were carried out with FACS-sorted cells, which were separated based only on their EGFP fluorescence. Details for the sorting are provided in [Figure S2](#mmc1){ref-type="supplementary-material"}A. The identical approach was also used to obtain sorted RN5 cells ([Figure S2](#mmc1){ref-type="supplementary-material"}B). We screened the sorted cells for *ALDH1A1*, *KLF4*, and *c-MYC*, which were all increased in ZL55-SO^high^ cells ([Figures S1](#mmc1){ref-type="supplementary-material"}D and S1E). In the sorted murine RN5-SO^high^ cells, besides *Sox2* and *Oct4*, the stem cell marker *Nanog* was also significantly increased ([Figure S1](#mmc1){ref-type="supplementary-material"}F). A hallmark for putative MM and other tumor type-derived CSCs is their increased resistance toward chemotherapeutic drugs including cis-Pt, as also reported previously for ovarian cancer-derived CSCs ([@bib31]). ZL55-SO and ZL55-SO-P2 cells were treated with cis-Pt concentrations ranging from 0.625 to 10 μM, and cell survival was assessed 5 days later ([Figure 2](#fig2){ref-type="fig"}A, left panel). Half maximal inhibitory concentration (IC~50~) values were 0.92 μM for ZL55-SO and 2.13 μM for ZL55-SO-P2 cells, indicating that the EGFP(+) cells displayed higher chemoresistance, i.e., higher survival than the non-selected ZL55-SO cells. While ZL55-SO-P2 cells were almost completely resistant to 1.25 μM cis-Pt as shown by nearly identical growth curves of cis-Pt-exposed and untreated cells, the growth/survival of ZL55-SO cells was considerably impaired under these conditions ([Figure 2](#fig2){ref-type="fig"}C). Of note, in ZL55-SO cells, the cells surviving the cis-Pt treatment were to a large extent EGFP(+) cells ([Figure 2](#fig2){ref-type="fig"}D) present at about 5% in the non-selected ZL55-SO cells ([Figures 1](#fig1){ref-type="fig"}B and 1C). Also, the sorted ZL55-SO^low^ and ZL55-SO^high^ cells were exposed to cis-Pt and IC~50~ values were determined ([Figures 2](#fig2){ref-type="fig"}A and 2B). The increase in survival of ZL55-SO^high^ cells compared with ZL55-SO^low^ cells in the presence of cis-Pt was qualitatively similar to that in the puromycin-selected ZL55-SO-P2 versus ZL55-SO cells ([Figure 2](#fig2){ref-type="fig"}A). With respect to the increased resistance, the ratio of IC~50~ values for the EGFP(+)-sorted cells (2.7-fold) was slightly higher than for the -SO-P2 versus -SO cells (1.9-fold); the smaller difference in the puromycin-selected cells likely being due to the presence of approximately 5% of EGFP(+) cells in the parental (unsorted) -SO cell population. Sorted cells were also exposed to 5-fluorouracyl (5-FU) and to the FAK inhibitor VS-6063, also known as defactinib. IC~50~ values are summarized in [Figure 2](#fig2){ref-type="fig"}B. Of note, no differences were detected in ZL55-SO^low^ and ZL55-SO^high^ cells with respect to their 5-FU sensitivity. In line with previous observations that FAK signaling is increased and functionally relevant in putative CSCs ([@bib24]), ZL55-SO^high^ cells were more susceptible toward the FAK inhibitor than the ZL55-SO^low^ cells ([Figures 2](#fig2){ref-type="fig"}A and 2B).

SOX2/OCT4-Expressing CSC-Enriched MM Cells Show Stem Cell Properties In Vitro {#sec2.2}
-----------------------------------------------------------------------------

An essential property of stem cells is asymmetric cell division, i.e., the ability to generate two daughter cells with non-identical properties. We hypothesized that in ZL55-SO-P2 EGFP(+) cells not continuously subjected to puromycin selection or in FACS-sorted ZL55-SO^high^ cells, a fraction of cells would eventually lose EGFP expression, possibly resulting from asymmetric cell division and/or a dynamic switch in CSC differentiation state ([Movie S1](#mmc2){ref-type="supplementary-material"}). While 1 day after puromycin removal essentially all cells were EGFP(+), at later time points (days 6, 71, and 80), first individual EGFP(−) cells and at later stages entire cell clusters of EGFP(−) cells were observed ([Figure 3](#fig3){ref-type="fig"}A and [Movie S2](#mmc3){ref-type="supplementary-material"}). Asymmetric cell divisions were documented by time-lapse videos, where mitosis of an EGFP(+) cell resulted in a green and a non-green daughter cell ([Movie S1](#mmc2){ref-type="supplementary-material"}). A decrease of EGFP(+) cells by 13% was observed at day 80 (10 passages) ([Figure 3](#fig3){ref-type="fig"}B and [Movie S2](#mmc3){ref-type="supplementary-material"}), and green cells decreased even more after long-term culturing in vitro (data not shown). Their advancement in differentiation from EGFP(+) to EGFP(−) cells was confirmed by their subsequent increased NF2 susceptibility ([Movie S4](#mmc5){ref-type="supplementary-material"}). Of note, within the population of EGFP(+) cells, a second population of cells appeared with a weaker green fluorescence intensity, close to the gating boundaries separating EGFP(+) and EGFP(−) cells ([Figure 3](#fig3){ref-type="fig"}B). We conclude that EGFP expression is not based on an all-or-none mechanism, but it exists rather as a continuum of cells with different SOX2/OCT4-based reporters as shown by the heterogeneous EGFP levels possibly resulting from a switch in CSC differentiation state.

SOX2/OCT4-Expressing CSC-Enriched MM Cells Are Present in Cell Lines Derived from All Human MM Histotypes and Also in Murine RN5 MM Cells {#sec2.3}
-----------------------------------------------------------------------------------------------------------------------------------------

Patients with sarcomatoid and biphasic MM have a poorer prognosis than patients diagnosed with an epithelioid MM ([@bib6]). Thus, we set out to investigate whether high SOX2/OCT4-expressing cells were present in cell lines derived from all different MM histotypes and to determine the proportion of EGFP(+) cells. EGFP(+) cell populations were detected in ZL55 (epithelioid), MSTO-211H, SPC111 (biphasic), and murine RN5 (sarcomatoid) cells; their fractions ranged from 4.8% to 7.8% ([Table 1](#tbl1){ref-type="table"}). Thus, in all three histotype-derived MM cell lines, EGFP(+), CSC-enriched cell populations were identified. Murine EGFP(+) RN5 cells were used in a syngeneic orthotopic in vivo mouse model aimed at demonstrating that the decrease of EGFP(+) cells observed in culture is not an artifact of in vitro cell culture conditions and/or specific for a certain MM cell line. Sorted RN5-SO^high^ cells were used in an in vivo allograft C57Bl/6J mouse model. Intraperitoneal (i.p.) injection of these cells resulted in tumor nodules after 8 weeks; staining of fixed tumors with a pan-cytokeratin (CK) antibody allowed identification of the tumor cells, further confirmed by double staining for EGFP ([Figure 3](#fig3){ref-type="fig"}C). The tumor contained patches of cells with strong EGFP expression, but also regions with weak or absent expression, although these cells were clearly CK positive, i.e., tumor cells. This indicates that a fraction of EGFP(+) tumor cells had lost SOX2/OCT4-driven reporter expression over time in vivo. Furthermore, RN5-SO^high^-sorted cells were transduced with NLS-mCherry and injected (i.p.) into mice. Tumors were collected after 8 weeks and isolated tumor cells were cultured in vitro for analysis. Among the NLS-mCherry-labeled RN5 MM cells, a fraction of EGFP(−) cells was detected (marked by arrows; [Figure 3](#fig3){ref-type="fig"}D). In addition, these NLS-mCherry-transduced RN5-SO^high^ cells were cultured in vitro for an additional 57 days. Cells were analyzed weekly by FACS; the fraction of EGFP(−) cells increased from 0.4% to 22.2% after 57 days, while the fraction of NLS-mCherry(−) cells only decreased by 0.8% in the same time period ([Figure 3](#fig3){ref-type="fig"}E). An overlay of the green and red cell populations present in cell cultures after 57 days in vitro revealed a left shift of the green cells toward lower fluorescence (increase in EGFP(−) cells), while at the same time the cluster of red cells did not move ([Figure 3](#fig3){ref-type="fig"}E). This indicates a selective decrease of EGFP(+) cells over time, i.e., SOX2/OCT4 levels had dropped below the threshold to maintain EGFP expression.

Tumor Growth of ZL55-SO^high^ Cells In Vivo Strongly Indicates CSC Properties {#sec2.4}
-----------------------------------------------------------------------------

The growth of FACS-sorted ZL55-SO^low^ and ZL55-SO^high^ cells was investigated in vivo in an orthotopic xenograft mouse model. Non-obese diabetic (NOD)/severe combined immunodeficiency (SCID) gamma mice were injected i.p. with 100,000 of either sorted ZL55-SO^low^ or ZL55-SO^high^ cells and the formation of tumor nodules was analyzed 5 weeks after injection. All mice exposed to either cell subpopulation showed macroscopic tumor formations on both the parietal and visceral part of the tunica serosa ([Figure 4](#fig4){ref-type="fig"}A). We measured semi-quantitatively the relative surface area covered by tumor tissue; a clearly larger surface area covered by visually discernible tumor nodules after injection of ZL55-SO^high^ cells was observed ([Figure 4](#fig4){ref-type="fig"}B). In some cases nearly the entire parietal tunica serosa of mice injected with ZL55-SO^high^ cells was covered with tumor nodules, but to a lesser extent also the visceral tunica serosa of different organs was covered ([Figure 4](#fig4){ref-type="fig"}A). The semi-quantitative analyses showed that the tumor-initiating capacity of ZL55-SO^high^ EGFP(+) cells was clearly higher than that of ZL55-SO^low^ EGFP(−) cells. Histological analyses of selected ZL55-SO^high^ tumor nodules showed irregularly formed boundaries between liver tissue and tumor mass, indicative of a highly invasive tumor ([Figure 4](#fig4){ref-type="fig"}C).

Characteristics of RN5-SO^high^ Tumor Cell Growth In Vivo Are Different from the One after Injection with RN5-SO^low^ Cells {#sec2.5}
---------------------------------------------------------------------------------------------------------------------------

A limited dilution assay was carried out, where different amounts of FACS-sorted murine MM cells (RN5-SO^high^ and RN5-SO^low^; 5,000, 50,000, and 500,000 cells per mouse) were injected i.p. in syngeneic C57Bl/6J mice. At three time points 13, 11, and 8 weeks post injection, mice with the largest initial load analyzed after the shortest period were killed and the tumor load/tumor size was investigated semi-quantitatively, first at the macroscopic level and then in more detail on histological sections ([Figure 5](#fig5){ref-type="fig"}). Injection of EGFP(−) RN5-SO^low^ cells resulted in the formation of macroscopically discernable tumors in 1 of 12 mice (8.3%); the tumor localization was intramuscular ([Figure 5](#fig5){ref-type="fig"}C). More tumors (in 6 of 12 mice; 50%) were detected after injection of RN5-SO^high^ cells; an example of an externally visible tumor of RN5-SO^high^ cells is shown in [Figure 5](#fig5){ref-type="fig"}B. Histological analyses revealed that RN5-SO^high^-derived tumors often localized within the subcutaneous connective tissue, in intramuscular regions of the abdominal wall, but also on the kidney capsule ([Figures 5](#fig5){ref-type="fig"}D--5G). Different tissue samples containing small tumor masses from mice injected with either RN5-SO^high^ and RN5-SO^low^ cells were histologically examined. In the RN5-SO^low^ group, tumors were identified in 4 of 12 (33%) mice and clearly more (9 of 12 mice; 75%) in mice injected with RN5-SO^high^ cells ([Figure 5](#fig5){ref-type="fig"}A). The tumor incidence in RN5-SO^high^-injected mice was higher at all three doses of tumor cells tested ([Figure 5](#fig5){ref-type="fig"}A). The calculated tumor-initiating frequency using the ELDA software ([@bib16]) for RN5-SO^high^ cells was clearly higher than for RN5-SO^low^ cells (ratio RN5-SO^high^/RN5-SO^low^, 17.4; p = 0.0063). Thus, also in vivo, EGFP(+) RN5-SO^high^ cells fulfill the criteria of CSC-enriched cells shown by their increased tumor-initiating frequency.

Increased In Vitro Self-Renewal Properties of RN5-SO^high^ and ZL55-SO^high^ Cells Compared with the Corresponding -SO^low^ Subpopulations {#sec2.6}
------------------------------------------------------------------------------------------------------------------------------------------

Other important CSC characteristics include an augmented capacity for self-renewal and also for anchorage-independent growth in vitro ([@bib21]). Self-renewal was assessed in ZL55 and RN5 cells by a limiting dilution assay as described previously ([@bib26], [@bib27]) using sorted -SO^low^ and -SO^high^ cells of both cell types. In both cell lines, the self-renewal capacity of EGFP(+) cells was clearly increased ([Figures S3](#mmc1){ref-type="supplementary-material"}A and S3B). Examples of EGFP(−) and EGFP(+) RN5 tumor spheres initiated from 10 cells/well and maintained in culture for 10 days are shown in [Figures S3](#mmc1){ref-type="supplementary-material"}C and S3D, respectively; the larger size of EGFP(+) tumor spheres was evident. In addition, the anchorage-independent growth in soft agar was investigated in the same cell lines. The average colony size of EGFP(+) RN5-SO^high^ cells after 2 weeks ([Figure S3](#mmc1){ref-type="supplementary-material"}E) was considerably larger than the size of the corresponding EGFP(−) RN5-SO^low^ colonies ([Figure S3](#mmc1){ref-type="supplementary-material"}F). Assuming a spherical shape of the colonies, based on the areas of the colonies depicted in [Figures S3](#mmc1){ref-type="supplementary-material"}E and S3F, the radius of a sphere was calculated. The average radius was significantly larger in RN5-SO^high^ cells than in the RN5-SO^low^ cells ([Figure S3](#mmc1){ref-type="supplementary-material"}H). The differences in radii were smaller between EGFP(−) and EGFP(+) ZL55 cell colonies; however, radii of ZL55-SO^high^ cell colonies were still significantly larger than the ones from EGFP(−) cells ([Figure S3](#mmc1){ref-type="supplementary-material"}G).

Decreased Susceptibility of EGFP(+) ZL55 Cells to Asbestos-Induced Acute Cytotoxicity, but Unaltered Cell Mobility In Vitro {#sec2.7}
---------------------------------------------------------------------------------------------------------------------------

CSCs are known to show higher resistance to exposure to cytotoxic agents ([@bib29]), possibly linked to their lower proliferation rates, while increased spreading of tumor cells to sites distant from the primary tumor are associated with augmented invasiveness and increased metastatic potential ([@bib2]). ZL55-SO-P2 EGFP(+) cells were significantly more resistant toward crocidolite-induced acute cytotoxicity (5 μg/cm^2^ of crocidolite for 96 hr) than EGFP(−) cells ([Figure 6](#fig6){ref-type="fig"}A). At 96 hr the MTT signal of ZL55-SO-P2 crocidolite-treated cells was only slightly lower than in control ZL55-SO-P2 cells, indicating an almost complete protection of EGFP(+) cells. Real-time growth curves of control ZL55-SO and ZL55-SO-P2 cells did not reveal large differences in the proliferation rates of the two cell populations ([Figures 6](#fig6){ref-type="fig"}C and 6D). The MTT signal at 120 hr post-plating for EGFP(−) ZL55-SO^low^ cells was slightly larger than for EGFP(+) ZL55-SO^high^ cells, in line with slower growth of CSCs (data not shown). Yet in a 2D scratch assay, the wound closure time was indistinguishable (data not shown). A more detailed analysis of the mobility of individual cells preferentially toward the cell-devoid area showed a faster cell movement of both cell groups directly following the scratch and lasting for about 2 hr, followed by a constant displacement of approximately 2 μm/5 min for the next 16 hr ([Figure S4](#mmc1){ref-type="supplementary-material"}C). Mobility of ZL55-SO cells grown at low confluence, i.e., allowing for non-directed movement was also not different between EGFP(+) and EGFP(−) cells ([Figure S4](#mmc1){ref-type="supplementary-material"}C). In addition, we used MSTO-211H cells, an MM cell line prone to form spheroids when grown in the absence of serum, to analyze the spheroid formation capacity ([@bib22]). MSTO-211H-SO-P2 cells consisting of mostly EGFP(+) cells showed qualitatively a larger number of spheroids (data not shown) that were also bigger than the ones from unsorted MSTO-211H-SO cells ([Figures S4](#mmc1){ref-type="supplementary-material"}A and S4B). Of note, spheroids produced from unsorted MSTO-211H-SO cells containing initially ∼7% of EGFP(+) cells were mostly made up of the EGFP(+) cell subpopulation, suggesting that mostly EGFP(+) cells show the propensity of forming spheroids ([Figure S4](#mmc1){ref-type="supplementary-material"}A).

Similar Sensitivity of EGFP(+) and EGFP(−) MM Cells to Calretinin Downregulation, but Pronounced Differences with Respect to Ectopic Expression of the Functional Tumor Suppressor NF2 and to the FAK Inhibitor VS-6063 {#sec2.8}
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Although the precise role of the positive MM marker calretinin (*CALB2*) is currently unknown, its downregulation in ZL55 cells by a lentivirus-mediated short hairpin RNA (shRNA) approach leads to massive apoptosis and necrosis, most strongly in epithelioid MM ([@bib7]). Of note, calretinin protein levels were similar in ZL55-SO and ZL55-SO-P2 cells ([Figure 6](#fig6){ref-type="fig"}G) and, more importantly, downregulation with shCALB2 no. 5, shCALB2 no. 7 ([@bib7]), and very efficiently with shCALB2 no. 84 (targeting the CALB2 3′ UTR) affected the survival of ZL55-SO and ZL55-SO-P2 cells to a similar extent ([Figure 6](#fig6){ref-type="fig"}B). Thus, unlike the situation with the FAK inhibitor VS-4718 that preferentially affects ALDEFLUOR(+), CSC-enriched MM cells ([@bib24]), *CALB2* downregulation equally affected proliferation and viability of ZL55 EGFP(+) and EGFP(−) cells. These results underscore calretinin as an interesting target for the elimination of calretinin-positive MM cells irrespective of their stemness.

Genes that are downregulated or lost in MM and are thought to act as a driver for MM formation include *NF2* (neurofibromatosis 2, merlin), *CDKN2A*, and *BAP1* ([@bib34]). Loss of functional NF2 resulting from mutations is observed in 40%--50% of human MPM ([@bib5]) and, moreover, low NF2-expressing MPM cells show a higher sensitivity toward FAK inhibition-induced growth arrest, while NF2 overexpression results in an increased resistance to the FAK inhibitor VS-4718 that preferentially affects ALDEFLUOR(+) CSC-enriched cells ([@bib24]). Thus, we investigated how overexpression of human wild-type NF2 affected proliferation and/or survival of EGFP(+) and EGFP(−) MM cells. The proliferation of control ZL55-SO and ZL55-SO-P2 was rather similar, a plateau was reached between 70 and 80 hr after plating ([Figures 6](#fig6){ref-type="fig"}C and 6D). Overexpression of NF2 ([Figures 6](#fig6){ref-type="fig"}C--6F) selectively affected EGFP(−) ZL55-SO cells, as shown by an almost complete cell growth arrest and cell death ([Figures 6](#fig6){ref-type="fig"}C--6F). NF2-overexpressing EGFP(+) ZL55 cells showed the typical epithelioid morphology, while neighboring EGFP(−) cells were characterized by rounding up and cell protrusions typical for dying (apoptotic/necrotic) cells ([Figures 6](#fig6){ref-type="fig"}E and 6F; [Movies S3](#mmc4){ref-type="supplementary-material"} and [S4](#mmc5){ref-type="supplementary-material"}). NF2 upregulation only marginally affected the proliferation of EGFP(+) ZL55-SO-P2 cells ([Figure 6](#fig6){ref-type="fig"}D), and the cell morphology was unaltered ([Figures 6](#fig6){ref-type="fig"}E and 6F). Nearly identical results were obtained with human MSTO-211H, SPC111, and ZL5 cells ([Figures S4](#mmc1){ref-type="supplementary-material"}E--S4J). The slow and delayed increase in the proliferation of ZL55-SO-NF2 cells was the result of the low percentage (5%) of EGFP(+) cells present in the unselected (-SO) cells, since nearly all cells were green at 120 hr ([Figure S4](#mmc1){ref-type="supplementary-material"}F). A similar effect was also seen with murine RN5 cells. The smaller magnitude of the effect might be linked to the fact that human, not mouse NF2, was overexpressed in the mouse cells. Thus, in line with previous reports demonstrating that NF2 upregulation in MM cells leads to growth inhibition and apoptosis ([@bib33]), NF2 overexpression blocked proliferation only in -SO cells mostly consisting of EGFP(−) cells, while barely affecting EGFP(+) cells. Thus, in contrast to the EGFP(−) cells, the CSC-enriched population derived from all MM histotypes was rather insensitive to NF2 overexpression. On the other hand, the FAK inhibitor VS-6063 more efficiently decreased cell proliferation in ZL55-SO-P2 EGFP(+) cells compared with ZL55-SO cells ([Figures 2](#fig2){ref-type="fig"}A and 2B).

Discussion {#sec3}
==========

MM are exceptionally resistant to therapeutic interventions such as chemotherapy, radiotherapy, surgery, and combinations thereof. In many instances therapy resistance is linked to a particular microenvironment ([@bib18]) created and maintained by the tumor tissue and, moreover, by the heterogeneity of the tumor cells within the tumor mass ([@bib4]). A small subpopulation of cancer cells with stem cell features termed CSCs, or functionally defined as TICs, is assumed to play a crucial role in the development of cancer and in promoting its sustained growth and the invasive and metastatic properties ([@bib23]). Evidence has accumulated that these CSCs are characterized by higher levels of pluripotency factors including SOX2, OCT4, and NANOG. Based on this, methods have been developed to isolate this cell subpopulation as applied in our study. Other approaches to isolate/enrich CSCs exploit specific properties such as enhanced levels of dye-exclusion transporters (*ABCG2*), increased aldehyde dehydrogenase activity (*ALDH1*), or their increased propensity to generate spheroids ([@bib22]). While the latter methods might modify these cells to some extent by the selection method, the SOX2/OCT4 reporter approach minimally perturbs the endogenous intracellular environment (excluding the putative effects exerted by EGFP); it allows the identification and isolation of putative CSCs based on their endogenously elevated levels of SOX2/OCT4. Higher levels of SOX2 in glioblastoma were linked with an increased tumor-initiating ability ([@bib13]), in ovarian carcinoma associated with the stem cell state, and, in lung cancer, CSCs were required for growth and metastatic potential ([@bib32]). Moreover, elevated levels of OCT4 and other stemness markers in MM cells derived from mesospheres were paralleled by an increased tumor-initiating capacity ([@bib22]). Reporter approaches based on pluripotency factor binding have been successfully used for the enrichment and identification of CSCs in breast cancer ([@bib26], [@bib27]) and ovarian cancer ([@bib31]), the latter using a NANOG-based reporter. Strong EGFP expression in the lentivirus-mediated SOX2/OCT4-based reporter approach allowed us to isolate and characterize MM cells in vitro and furthermore to investigate in detail the properties of these cells in vivo. One of the main advantages of the reporter approach is the possibility of continuously monitoring these cells over time. This revealed that a fraction of initially EGFP(+) cells lost their green fluorescence, likely as the result of a decrease in SOX2/OCT4 levels insufficient to drive EGFP expression; time-lapse movies demonstrated this loss to occur often within one cell division. We attribute this to a dynamic shift in the differentiation state from EGFP(+) to EGFP(−) cells, the latter characterized by a more non-CSC phenotype as described in detail for breast cancer CSCs (see Figure 7D in [@bib1]). In agreement, the newly formed EGFP(−) cells were again equally susceptible to the anti-proliferative/pro-apoptotic action of elevated levels of NF2 as were the parental -SO EGFP(−) cells. This precludes the loss of EGFP being the result of, e.g., reporter silencing. This conclusion is also supported by the finding that the same MM cells constitutively expressing NLS-mCherry did not lose red fluorescence over time.

MM are considered as an example, where tumorigenesis is mostly driven by loss of tumor suppressor functions including genes such as *NF2* coding for merlin, *CDKN2A*, *CDKN2B*, or *BAP1* ([@bib17]). Accordingly, *NF2* is mutated in approximately 40% of all human MM ([@bib5]) and/or completely absent by allelic loss ([@bib9]). NF2 expression levels are strongly correlated with the sensitivity to inhibitors of FAK phosphorylation ([@bib24]). The FAK inhibitor VS-4718 efficiently inhibits proliferation of NF2(−) MM cells, while NF2(+) cells are rather insensitive to the inhibitor.

In our study, we compared the sensitivity of EGFP(+) and EGFP(−) MM cells with the effects of overexpression of NF2. In human NF2-overexpressing MM -SO cells, proliferation was almost completely blocked, while EGFP(+) CSC-enriched MM cell populations were barely affected by increased NF2 levels. This effect was completely independent from the NF2 status of the parental cells. NF2-negative ZL55 cells were equally affected, as were NF2-positive MSTO-211H cells. The apparently weaker effect in MSTO-211H-SO cells seen in the real-time growth curves ([Figure S4](#mmc1){ref-type="supplementary-material"}J) is essentially the result of the insensitivity of the small subpopulation of EGFP(+) MSTO-211H-SO cells to NF2 overexpression. Adenovirus-mediated expression of NF2 was previously shown to inhibit proliferation and to cause a G1 cell-cycle arrest in NF2-deficient tumor cells ([@bib33]). Detailed analyses of NF2-overexpressing ZL55-SO mostly comprising EGFP(−) cells revealed not only a proliferation-inhibiting effect, but considerable cell death caused by elevated NF2 levels. Inhibition of FAK signaling by VS-6063 preferentially affected EGFP(+) ZL55 cells, indicating that a direct impairment of FAK signaling in CSC-enriched ZL55 cells might be the more promising strategy than the likely indirect effect on FAK signaling inhibition by NF2 upregulation that mostly affected the EGFP(−) ZL55 cells.

Since downregulation of calretinin decreases the viability and proliferation of MM cells in vitro ([@bib7]), we investigated the effects of decreasing calretinin expression in EGFP(+) and EGFP(−) cells. Interestingly, shRNA CALB2-mediated downregulation equally affected both cell populations with respect to proliferation and cell death. Thus, calretinin remains an interesting target to eradicate both MM CSCs and non-CSCs.

The limited dilution assay remains the gold standard for the identification and characterization of CSC- or TIC-enriched cell populations. Here we have chosen two orthotopic i.p. models presuming that tumor cells encounter an environment that is more relevant with respect to human MM pathology (a lumen covered by the mesothelium) than in the more often used subcutaneous models ([@bib22], [@bib24]). In the xenograft model using human ZL55 cells, formation of tumor nodules covering the parietal as well as the visceral mesothelium was clearly increased when injecting EGFP(+) cells in comparison with injection-treated with unsorted ZL55, comprising less than 5% of EGFP(+) cells. In the physiologically more relevant allograft model using C57BL/6J mice characterized by their highly competent immune system and the previously established mouse MM cell line RN5 ([@bib8]), the tumor-initiating capacity of EGFP(+) RN5 cells was almost 20-fold higher than that of EGFP(−) RN5 cells. Of note, the initial tumor cell load to induce i.p. tumor nodules with RN5 cells was significantly higher than the number of mouse MM87 cells that were injected subcutaneously (s.c.) in the NOD/SCID mouse model ([@bib24]). To summarize, both normal (C57BL/6J) versus compromised (NOD/SCID) immune system cells, and orthotopic versus s.c. injection cells, might contribute to the higher tumor cell (RN5) load required for MM formation in vivo.

In comparison with CSCs from tumors derived from other tissues, the nature of MM CSCs with respect to niche, interactions with the microenvironment, and most importantly the immune system and other properties in vivo are as yet under exploited. We estimate that the EGFP-based approach will allow also to visualize EGFP(+) cell fate in the intact tumor microenvironment in the pleural or peritoneal cavities, e.g., for detailed longitudinal studies in vivo. In most previous studies, e.g., involvement of SOX2 in self-renewal ([@bib3]) or tumor-initiating capability ([@bib13]) and the role of OCT4 in dedifferentiation and stemness of cancer cells ([@bib20]) has been investigated separately. Finally, we propose that the same approach might be applied for primary (non-transformed) mesothelial cells. Such studies might shed light on the role of normal mesothelial stem cells in the process of transformation to MM. The insights into MM CSC biology provided here are expected to be relevant in the search for innovative approaches to target this critically important MM cell population.

Experimental Procedures {#sec4}
=======================

Cell Culture and Selection of SOX2/OCT4-Expressing Cells {#sec4.1}
--------------------------------------------------------

MM cell lines were cultured as described above, transduced with lentivirus containing SOX2/OCT4 stemness indicator constructs (for details, see the [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}) resulting in "MM-SO" cells consisting of EGFP(+) and EGFP(−) subpopulations. Treatment with either 2 or 10 μg/mL of puromycin for 10 days led to an enrichment of EGFP(+) cells. In some experiments, ZL55-SO cells were exposed to 2 or 10 μg/mL of puromycin for 3 weeks, followed by a growth period of 3 weeks (10 passages) without puromycin. Cells were then analyzed by flow cytometry for EGFP expression.

Flow Cytometry Analysis of EGFP(+) Cells {#sec4.2}
----------------------------------------

Trypsinized MM cells were analyzed by FACS on a BD Accuri C6 (BD Biosciences); details are described in the [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}. Sorting of EGFP(+) and EGFP(−) cells was performed on a BD FACSAria (BD Biosciences) cell sorter and selected cells were used for subsequent cell culture experiments in vitro.

Determination of the mRNA Expression of Stemness Gene Levels by qRT-PCR {#sec4.3}
-----------------------------------------------------------------------

Total RNA extracted from 80% confluent cell cultures (peqGOLD TriFast) of puromycin-selected or sorted ZL55-SO or RN5-SO cells was used for qRT-PCR following the manufacturer\'s instructions (QIAGEN). qRT-PCR primer sequences are listed in the [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

Treatment of Cells with cis-Pt, 5-FU, and VS-6063 and Determination of IC~50~ Values {#sec4.4}
------------------------------------------------------------------------------------

Cells (500/well for cis-Pt and 5-FU experiments and 2,000/well for VS-6063) were seeded in 96-well plates and grown for 24 hr. Drugs were added at different concentrations (for details, see the [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}) and the MTT assay was performed at 48, 96, or 120 hr post treatment (depending on the drug) to determine IC~50~ values. Additionally, real-time cell-proliferation curves were acquired with the IncuCyte Live-Cell Imaging System (Essen BioScience).

In Vivo Limiting Dilution Assay {#sec4.5}
-------------------------------

Animal experiments were performed with the permission of the local animal care committee (Canton of Fribourg, Switzerland) and according to the present Swiss law and the European Communities Council Directive of 24 November 1986 (86/609/EEC). Murine RN5-SO^low^ and RN5-SO^high^ cells were resuspended in 200 μL PBS and injected i.p. in C57Bl/6J mice (four mice per group, three different concentrations). Cells (5,000, 50,000, and 500,000) were injected and groups killed in parallel after 13, 11, and 8 weeks, respectively. Photographs were taken to show macroscopic tumor appearance. Organ samples were collected (diaphragm, spleen, liver, and peritoneal wall) for histological analysis. Sorted ZL55-SO^low^ and ZL55-SO^high^ cells (100,000/mouse) were injected into NOD/SCID gamma mice (four to five mice per group).

Western Blot Assays for Calretinin, NF2, and Mesothelin {#sec4.6}
-------------------------------------------------------

Proteins were extracted from washed cell pellets (from 70% to 90% confluent cultures) using standard RIPA buffer (for details, see the [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}). From the cleared supernatant, proteins (50 μg) were separated on 10% polyacrylamide SDS gels and transferred onto nitrocellulose membranes. After blocking, membranes were first incubated with antibodies against calretinin, mesothelin, or NF2, followed by the ABC detection system using the horseradish peroxidase substrate (Millipore, Luminata Forte); membranes were imaged on the western blot reader FluorChem E System (Bucher Biotec).

Downregulation of Calretinin in ZL55-SO and ZL55-SO-P2 Using Lentiviral-Mediated CALB2 shRNA and Upregulation of NF2 {#sec4.7}
--------------------------------------------------------------------------------------------------------------------

Cells (500/well in 96-well plates) were grown for 24 hr and transduced with lentivirus shRNA CALB2 nos. 5 and 7 ([@bib7]) or a novel 3′ UTR-targeted shRNA CALB2: 5′-CCG G[TT TAA CGC GAT CTT CAC ATT T]{.ul}CT CGA GAA ATG TGA AGA TCG CGT TAA ATT TTT TG-3′. MTT assays were performed at 120 hr post infection. For NF2 upregulation, cells were transduced with LV-NF2 and growth curves were determined by the IncuCyte system.

Supplemental Information {#app2}
========================

Document S1. Supplemental Experimental Procedures and Figures S1--S4Movie S1. A Small Cluster of EGFP(+) ZL55-SO Cells Consisting of a Mixed Population of Green and Non-green Cells Was SelectedMovie S2. Time-Lapse Series of ZL55-SO-P2 Cells Maintained in Culture In Vitro for 80 DaysMovie S3. Video of ZL55-SO Parental Cells (Mixed Population), where the Functional Human NF2 Tumor Suppressor Was OverexpressedMovie S4. Different Behavior of FACS-Sorted ZL55-SO^high^ Cells, Initially Consisting of 100% EGFP(+) CellsDocument S2. Article plus Supplemental Information
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![An EGFP Reporter-Based and Puromycin-Selected Subpopulation of ZL55 Cells Shows Higher Transcript Levels of CSC-Associated Genes\
(A) Schematic representation of the pL-SIN-EOS-S(4+)-EiP lentiviral (LV) construct with OCT4 (blue) and SOX2 (orange) binding sites. Binding of OCT4 and SOX2 initiates expression of EGFP and Puro^R^.\
(B) A small percentage of EGFP(+) cells is present in LV-transduced ZL55 cells (left panel, bright field image; right panel, fluorescence image).\
(C) FACS analysis reveals an EGFP(+) subpopulation of around 5% (C2); with the same gating only 0.05% of non-infected ZL55 cells are counted (C1).\
(D) Directly after puromycin selection stringent FACS analysis of ZL55-SO-P2 cells identifies 78.6% of cells as EGFP(+).\
(E) Puro^R^ selection results in a visibly 100% positive EGFP(+) ZL55-SO-P2 subpopulation (right); left image: bright field image of the same cells.\
(F) qRT-PCR reveals a 4.5-fold increase for *SOX2* expression in ZL55-SO-P2 and ZL55-SO-P10 cells (selected with 2 or 10 μg/mL of puromycin, respectively) compared with the non-selected ZL55-SO cells. *OCT4* levels are increased 1.9-fold in -P2 and nearly 6-fold in the -P10 cells. A significant increase in the expression of *ABCG2* as well as *CSF1R* is detected. Statistical comparisons were performed using a one-way ANOVA (^∗^p \< 0.05) from three independent experiments; error bars represent SD. See also [Figure S1](#mmc1){ref-type="supplementary-material"}.](gr1){#fig1}

![Higher Resistance of ZL55-SO^high^ EGFP(+) Cells Toward cis-Pt and 5-FU and a Lower One Toward VS-6063\
(A and B) Increased viability of ZL55-SO-P2 versus ZL55-SO cells exposed to cis-Pt (left panel) (A). From the curves derived from sorted ZL55-SO^low^ and ZL55-SO^high^ cells (right three panels), IC~50~ values for cis-Pt, 5-FU, and VS-6063 were calculated from three independent experiments and are shown in (B). ^∗∗∗^p \< 0.001; one-way ANOVA; n.s., not significant. ZL55-SO^high^ cells display higher susceptibility to VS-6063.\
(C) Real-time growth curves show the strong effect of cis-Pt (1.25 μM) on ZL55-SO cell proliferation/survival, while ZL55-SO-P2 cells are almost completely resistant. One representative experiment from three independent experiments.\
(D) Bright field and fluorescence images showing the effect of cis-Pt on ZL55-SO cells; the fraction of EGFP(+) cells is increased after cis-Pt exposure (right panels).](gr2){#fig2}

![Time-Dependent Decrease in EGFP Expression in Initially 100% EGFP(+) Cells Indicates Gradual Loss of Stemness Observed In Vitro and In Vivo\
(A) Example of EGFP(+) and EGFP(−) ZL55-SO cells in a cell culture dish initially plated with FACS-sorted ZL55-SO^high^ cells. At 80 days in vitro many non-green EGFP(−) cells are observed, often arranged in clusters (marked by yellow dotted lines) and EGFP(+) (examples marked by red dotted lines).\
(B) Decrease of the fraction of EGFP(+) cells starting from sorted ZL55-SO^high^ cells (initially 78.6% EGFP(+) cells) to 68.7% after culturing without puromycin selection for 35 days (ten passages). Note the appearance of a distinct population of cells with lower EGFP fluorescence (arrow).\
(C) Tumor tissue derived from a mouse injected with RN5-SO^high^ cells for 8 weeks in vivo. In the tumor mass identified by pan-cytokeratin (CK) immunohistochemistry (red fluorescence), clusters of cells with weak-to-none EGFP staining (green fluorescent image; left) are seen. Staining with DAPI (blue) allows better identification of individual cells. In the merged image, the presence of clusters of yellow cells (co-localization of CK and EGFP), but also of cells without EGFP (CK only) demonstrates loss of EGFP expression over time in vivo.\
(D) RN5-SO^high^ cells additionally expressing NLS-mCherry (red fluorescent nuclei) formed tumors in vivo as demonstrated after 8 weeks. Tumor-derived cells were cultivated in vitro and revealed that a fraction of NLS-mCherry(+) cells had lost EGFP expression (cells marked by arrows). In the merged image these cells appear as red only.\
(E) Cells shown in (D) were maintained in culture in vitro for an additional 57 days and analyzed by FACS for green (EGFP) and red (NLS-mCherry) fluorescence. While the fraction of NLS-mCherry(+) cells only marginally decreased from 99.8% to 99.0%, the fraction of EGFP(+) cells decreased from 99.6% to 77.8%. Note the left shift of the population of EGFP(+) cells: blue cloud at t1; red cloud at t57. See also [Figure S2](#mmc1){ref-type="supplementary-material"}.](gr3){#fig3}

![Increased Tumor Growth of Human ZL55-SO^high^ EGFP(+) Cells in NOD/SCID Gamma Mice\
(A) ZL55-SO^low^ and ZL55-SO^high^ cells (100,000/mouse) were injected i.p. into NOD/SCID gamma mice. Mice injected with ZL55-SO^high^ cells show an increased number/density of tumor nodules, especially visible on the visceral pleura (right images).\
(B) The percentage of tumor nodules covering the surface of the visible parietal and visceral peritoneum is 9.1% for ZL55-SO^low^ cells and 27.8% for ZL55-SO^high^ cells (^∗∗∗^p \< 0.001; one-way ANOVA). Average of four to five animals per group; error bars represent SD.\
(C) Tumor masses were histologically analyzed; a tumor nodule on the liver surface shows highly invasive edges (arrow). See also [Figure S3](#mmc1){ref-type="supplementary-material"}.](gr4){#fig4}

![Increased Tumor-Initiating Frequency and Morphological Aspects of RN5-SO^high^ EGFP(+) Cell-Derived Tumors in Syngeneic C57Bl/6J Mice\
RN5-SO^low^ and RN5-SO^high^ cells were injected i.p. in C57Bl/6J mice at three doses (500,000, 50,000, and 5,000 cells) and killed after 8, 11, and 13 weeks, respectively.\
(A) Fraction of mice with tumors found by microscopic analyses. At all injected doses of RN5 cells and time points, tumor incidence is higher with RN5-SO^high^ cells. The tumor-initiating frequency (TIF) was calculated for both groups.\
(B--F) H&E-stained sections. (B) Tumor of RN5-SO^high^ cells (500,000 cells at 8 weeks); tumor cells are located subcutaneously in the parietal wall. (C) Intramuscular tumor in the abdominal wall of the same mouse. (D) In the same group (500,000 cells at 8 weeks), tumor cell growth on the liver surface. (E) and (F) Intramuscular tumors in a mouse (50,000 RN5-SO^high^ cells at 8 weeks).\
(G) A parallel section of the one presented in (F) shows a Goldner staining to better emphasize the muscle tissue (red) and the connective tissue (green) in the tumor mass. Arrows in (F) and (G) indicate muscle fibers. See also [Figure S3](#mmc1){ref-type="supplementary-material"}.](gr5){#fig5}

![Decreased Susceptibility of EGFP(+) ZL55 Cells to Asbestos Toxicity and NF2 Expression; Equal Sensitivity of EGFP(+) and EGFP(−) ZL55 Cells to Calretinin Downregulation\
(A) Increased resistance of ZL55-SO-P2 cells exposed to 5 μg/cm^2^ of crocidolite for 96 hr determined by an MTT assay compared with ZL55-SO cells (n = 3 independent experiments, one-way ANOVA; ^∗∗∗^p \< 0.0005).\
(B--D) Downregulation of calretinin in ZL55-SO and ZL55-SO-P2 cells equally decreases the viability in both cell populations for three different shRNA targeting *CALB2* (B) (n = 3 independent experiments; one-way ANOVA; n.s., not significant). Overexpression of merlin (NF2) in ZL55-SO (C) and ZL55-SO-P2 cells (D) shows strong proliferation-inhibiting effects on the non-sorted ZL55-SO cells, but almost no effect on ZL55-SO-P2 cells. The inset in (D) shows strong upregulation of full-length NF2 (M~r~ = ∼68 kDa) using LV-NF2. All error bars represent SD.\
(E) Live-cell imaging of ZL55-SO 3 hr after upregulation of NF2; note the presence of EGFP(+) and EGFP(−) cells in the ZL55-SO cell population. The morphology of green and non-green cells is mostly epithelioid.\
(F) Twenty-seven hours post infection, the upregulation of NF2 induced strong apoptosis/necrosis in non-green cells (white arrows) demonstrated by cell shrinkage, blebbing, and cell debris. EGFP(+) cells do not show striking morphological changes.\
(G) Western blot analysis showing strong downregulation of CR (M~r~ = 31 kDa) by shRNA CALB2 no. 5 in ZL55-SO and ZL55-SO-P2 cells. At approximately 35 kDa, the nitrocellulose membrane was cut and the upper part was used for GAPDH detection (lower panel). Control infection with shRNA GFP has no effect on CR expression. For the normalization the signal for GAPDH (M~r~ ∼38 kDa) was used. See also [Figure S4](#mmc1){ref-type="supplementary-material"}.](gr6){#fig6}

###### 

Percentage of EGFP(+) Cell Populations in Human and Mouse MM Cell Lines

  Cell Line   Origin/Characterization   \% GFP(+) Cells
  ----------- ------------------------- -----------------
  ZL55        human/epithelioid         4.8
  SPC111      human/biphasic            6.2
  MSTO-211H   human/biphasic            6.1
  RN5         murine/sarcomatoid        7.8
